2. Search Result
Search Result
Results for "

exacerbations

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Peptides

1

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-66011
    Moxifloxacin Hydrochloride
    Maximum Cited Publications
    7 Publications Verification

    BAY 12-8039

    		 Bacterial Antibiotic Infection Cancer
    Moxifloxacin Hydrochloride (BAY 12-8039) is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
  • HY-W015815
    6-Methylnicotinamide

    		Endogenous Metabolite Neurological Disease
    6-Methylnicotinamide, a derivate of nicotinamide, is an endogenous metabolite. A sudden increase of 6-methylnicotinamide in the acute stages of intracerebral hemorrhage (ICH) exacerbates neurological damages.
  • HY-66011A
    Moxifloxacin
    Maximum Cited Publications
    7 Publications Verification

    BAY 12-8039 free base

    		 Bacterial Antibiotic Infection Cancer
    Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
  • HY-135398
    Decarboxy Moxifloxacin

    		Bacterial Inflammation/Immunology Infection
    Decarboxy Moxifloxacin (compound 8) is a decarboxylated compound of Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
  • HY-P2222
    DX600

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    DX600 is a selective ACE2 specific inhibitor (KD: 1.3 nM), and does not cross-react with ACE. DX600 exacerbates diabetes-induced cardiovascular dysfunction and the increase in cardiac and renal NOX activity.
  • HY-66011AS
    Moxifloxacin-d4

    BAY 12-8039-d4 free base

    		 Isotope-Labeled Compounds Bacterial Antibiotic Infection
    Moxifloxacin-d4 is the deuterium labeled Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
  • HY-66011AS2
    Moxifloxacin-d3 hydrochloride

    BAY 12-8039-d3

    		 Bacterial Antibiotic Cancer Infection
    Moxifloxacin-d3 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin hydrochloride is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2][3].
  • HY-66011S
    rac cis-Moxifloxacin-d4 hydrochloride

    rac cis-BAY 12-8039-d4

    		 Isotope-Labeled Compounds Bacterial Antibiotic Infection
    rac cis-Moxifloxacin-d4 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin Hydrochloride (BAY 12-8039) is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
  • HY-116229
    Gemifloxacin

    SB-265805; LB20304

    		 Antibiotic Bacterial Infection
    Gemifloxacin, a fluoroquinolone, is a potent and orally active antipneumococcal agent. Gemifloxacin shows bactericidal activity against highly quinolone-resistant pneumococci.Gemifloxacin can be used for the research of respiratory infections, such as community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis (AECB).
  • HY-66011B
    (Rac)-Moxifloxacin

    (Rac)-BAY 12-8039 free base

    		 Antibiotic Bacterial Infection
    (Rac)-Moxifloxacin ((Rac)-BAY 12-8039 free base) is the isoform of Moxifloxacin Hydrochloride (HY-66011), which is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
  • HY-B0024
    Prulifloxacin
    1 Publications Verification

    NM441

    		 Bacterial Antibiotic Infection
    Prulifloxacin (NM441) is an orally active fluoroquinolone antibiotic with a broad spectrum of activity against Gram-positive and -negative bacteria. Prulifloxacin is a proagent of a thiazeto-quinoline carboxylic acid derivative Ulifloxacin (NM394). Prulifloxacin has the potential for lower urinary tract infections and exacerbations of chronic bronchitis.
  • HY-136446
    MYLS22
    5 Publications Verification

    		 Others Cancer Cardiovascular Disease
    MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor. MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. MYLS22 can inhibit mitochondrial fusion and exacerbate the mitochondrial damage.
  • HY-B1810
    Tulobuterol
    1 Publications Verification

    C-78 free base

    		 Adrenergic Receptor Inflammation/Immunology Endocrinology
    Tulobuterol (C-78 free base) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol is also a sympathomimetic agent used as a transdermal patch, and increases normal diaphragm muscle strength.
  • HY-66011AS3
    Moxifloxacin-d3-1 hydrochloride

    BAY 12-8039-d3-1

    		 Isotope-Labeled Compounds Infection
    Moxifloxacin-d3-1 hydrochloride (BAY 12-8039-d3-1) is a deuterium labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
  • HY-66011AS4
    Moxifloxacin-13C,d3 hydrochloride

    BAY 12-8039-13C,d3

    		 Isotope-Labeled Compounds Cancer
    Moxifloxacin- 13C,d3 hydrochloride (BAY 12-8039- 13C,d3) is 13C and deuterated labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
  • HY-B1810S
    Tulobuterol-D9 hydrochloride

    C-78-d9

    		 Adrenergic Receptor Inflammation/Immunology Endocrinology
    Tulobuterol-d9 (hydrochloride) is the deuterium labeled Tulobuterol. Tulobuterol (C-78 free base) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol is also a sympathomimetic agent used as a transdermal patch, and increases normal diaphragm muscle strength[1].
  • HY-W011733
    Tulobuterol hydrochloride
    1 Publications Verification

    C-78

    		 Adrenergic Receptor Influenza Virus Antibiotic Infection Endocrinology Inflammation/Immunology
    Tulobuterol hydrochloride (C-78) is a long-acting β2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma. Tulobuterol hydrochloride is also a sympathomimetic agent used as a transdermal patch, increases normal diaphragm muscle strength. Tulobuterol hydrochloride inhibit rhinovirus replication and modulate airway inflammation.
  • HY-A0062
    Telithromycin
    5 Publications Verification

    HMR3647; RU66647

    		 Bacterial Antibiotic Infection Inflammation/Immunology
    Telithromycin (HMR3647) is a novel ketolide antibiotic that structurally resembles macrolides. Telithromycin belongs to the ketolide family that is characterized by a keto group at position 3 of the macrolide ring and is active against bacteria causing community-acquired pneumonia, acute exacerbation of chronic bronchitis, and acute sinusitis. Telithromycin also has similar immunomodulatory effects as macrolides. Telithromycin can be used for the research of respiratory infections including bronchial asthma.
  • HY-17452
    Cefditoren sodium

    ME 1206

    		 Bacterial Infection Inflammation/Immunology
    Cefditoren sodium (ME 1206) is a broad-spectrum, third-generation, oral cephalosporin antibacterial with enhanced stability against many common β lactamases. Cefditoren sodium has activity against Gram-negative organisms and Gram-positive organisms. Cefditoren sodium can be used in the research of infection diseases such as acute exacerbations of chronic bronchitis, community-acquired pneumonia (CAP), streptococcal pharyngitis/tonsillitis, or uncomplicated skin and skin structure infections.
  • HY-17452A
    Cefditoren (Pivoxil)

    Cefditoren pivoxyl; Cefditoren pivaloyloxymethyl ester; ME 1207

    		 Bacterial Antibiotic Infection Inflammation/Immunology
    Cefditoren Pivoxil (ME 1207) is a broad-spectrum, third-generation, oral cephalosporin antibacterial with enhanced stability against many common β lactamases. Cefditoren Pivoxil has activity against Gram-negative organisms and Gram-positive organisms. Cefditoren Pivoxil can be used in the research of infection diseases such as acute exacerbations of chronic bronchitis, community-acquired pneumonia (CAP), streptococcal pharyngitis/tonsillitis, or uncomplicated skin and skin structure infections.